SCAP gene polymorphisms decrease the risk of nonalcoholic fatty liver disease in females with metabolic syndrome

Journal of Genetics

Volumn 92, Issue 3, 2013, Pages 565-570

  Sun, Shanshan ^a   Wang, Mu ^a   Song, Haiyan ^a   Wu, Tao ^a   Wei, Huafeng ^a   He, Songhua ^a   DING, Zhaoguo ^b   Ji, Guang ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

genetic polymorphism; metabolic syndrome; nonalcoholic fatty liver disease; SCAP; SREBF 1; SREBF 2

Indexed keywords

MEMBRANE PROTEIN; SIGNAL PEPTIDE; SREBP CLEAVAGE ACTIVATING PROTEIN; SREBP CLEAVAGE-ACTIVATING PROTEIN;

AGED; ARTICLE; CASE CONTROL STUDY; DNA SEQUENCE; FATTY LIVER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; RISK; SEX RATIO; SEXUAL DEVELOPMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEQUENCE ANALYSIS, DNA; SEX CHARACTERISTICS; SEX DISTRIBUTION;

EID: 84899583059     PISSN: 00221333     EISSN: 09737731     Source Type: Journal    
DOI: 10.1007/s12041-013-0280-9     Document Type: Article

References (25)

1. Alberti K. G., Zimmet P. and Shaw J. 2005 The metabolic syndrome-a new worldwide definition. Lancet366, 1059-1062.
2. Almeda-Valdes P., Cuevas-Ramos D. and Aguilar-Salinas C. A. 2009 Metabolic syndrome and non-alcoholic fatty liver disease. Ann. Hepatol. 8, suppl 1, 18-24.
3. Assy N., Kaita K., Mymin D., Levy C., Rosser B. and Minuk G. 2000 Fatty infiltration of liver in hyperlipidemic patients. Dig. Dis. Sci. 45, 1929-1934.
4. Brunt E. M. 2010 Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7, 195-203.
5. Buetow K. H., Edmonson M., MacDonald R., Clifford R., Yip P., Kelley J. et al. 2001 High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc. Natl. Acad. Sci. USA98, 581-584.
6. Carlson C. S., Eberle M. A., Rieder M. J., Yi Q., Kruglyak L. and Nickerson D. A. 2004 Selecting a maximally informative set of single nucleotide polymorphisms for association analyses using linkage disequilibrium. Am. J. Hum. Genet. 74, 106-120.
7. Chatrath H., Vuppalanchi R. and Chalasani N. 2012 Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin. Liver Dis. 32, 22-29.
8. Chen S. H., He F., Zhou H. L., Wu H. R., Xia C. and Li Y. M. 2011 Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J. Dig. Dis. 12, 125-130.
9. Fan Y. M., Laaksonen R., Janatuinen T., Vesalainen R., Nuutila P., Knuuti J. et al. 2001 Effects of pravastatin therapy on serum lipids and coronary reactivity are not associated with SREBP cleavage-activating protein polymorphism in healthy young men. Clin. Genet. 60, 319-321.
10. Fiegenbaum M., Silveira F. R., van der Sand C. R., van der Sand L. C., Ferreira M. E., Pires R. C. et al. 2005 Determinants of variable response to simvastatin treatment: the role of common variants of SCAP, SREBF-1a and SREBF-2 genes. Pharmacogenomics J. 5, 359-364.
11. Hjelkrem M. C., Torres D. M. and Harrison S. A. 2008 Nonalcoholic fatty liver disease. Minerva Med. 99, 583-593.
12. Horton J. D., Goldstein J. L. and Brown M. S. 2002 SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109, 1125-1131.
13. Juran B. D. and Lazaridis K. N. 2006 Genomics and complex liver disease: challenges and opportunities. Hepatology44, 1380-1390.
14. Kojima S., Watanabe N., Numata M., Ogawa T. and Matsuzaki S. 2003 Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 38, 954-961.
15. Korn B. S., Shimomura I., Bashmakov Y., Hammer R. E., Horton J. D., Goldstein J. L. et al. 1998 Blunted feedback suppression of SREBP processing by dietary cholesterol in transgenic mice expressing sterol-resistant SCAP(D443N). J. Clin. Invest. 102, 2050-2060.
16. Li S. L., Yang Q., Lv S. Y., Zhang Y. L. and Zhang J. A. 2012 Prevalence of the metabolic syndrome in the Yan-an region of northwest China. J. Int. Med. Res. 40, 673-680.
17. Matsuda M., Korn B. S., Hammer R. E., Moon Y. A., Komuro R., Horton J. D. et al. 2001 SERBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 15, 1206-1216.
18. Moon Y. A., Liang G., Xie X., Frank-Kamenetsky M., Fitzgerald K., Koteliansky V. et al. 2012 The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15, 240-246.
19. Pagadala M. R. and McCullough A. J. 2012 Editorial: non-alcoholic fatty liver disease and obesity: not all about body mass index. Am. J. Gastroenterol. 107, 1859-1861.
20. Salek L., Lutucuta S., Ballantyne C. M., Gotto Jr A. M. and Marian A. J. 2002 Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J. Mol. Med. (Berl.)80, 737- 744.
21. Song J., da Costa K. A., Fischer L. M., Kohlmeier M., Kwock L., Wang S. et al. 2005 Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). FASEB J. 19, 1266-1271.
22. Suzuki A., Lindor K., St Saver J., Lymp J., Mendes F., Muto A. et al. 2005 Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J. Hepatol. 43, 1060-1066.
23. Wanless I. R. and Lentz J. S. 1990 Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology12, 1106-1110.
24. Zeng M. D., Fan J. G., Lu L. G., Li Y. M., Chen C. W., Wang B. Y. et al. 2008 Chinese National Consensus Workshop on Nonalcoholic Fatty Liver Disease. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J. Dig. Dis. 9, 108-112.
25. Zhou Y. J., Li Y. Y., Nie Y. Q., Yang H., Zhan Q., Huang J. et al. 2010 Influence of polygenetic polymorphisms on the susceptibility to non-alcoholic fatty liver disease of Chinese people. J. Gastroenterol. Hepatol. 25, 772-777.